Cannabis Use Disorder Market Report Highlights Epidemiology, Emerging Therapies and Growth Opportunities Through 2034
Dublin, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Use Disorder - Market Insight, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.
The comprehensive report, "Cannabis Use Disorder (CUD) - Market Insights, Epidemiology, and Market Forecast - 2034," provides an in-depth assessment of the cannabis use disorder market, patient population, current treatment landscape, clinical pipeline and commercial outlook across the seven major markets. Coverage includes the United States, Germany, France, Italy, Spain, the United Kingdom and Japan for the 2020-2034 study period.
Key Cannabis Use Disorder Market Highlights
Cannabis Use Disorder Epidemiology and Disease Burden
The report evaluates historical and projected total prevalent, diagnosed, age-specific, gender-specific and treated cases of cannabis use disorder. It also examines epidemiological trends, diagnostic practices, prescription patterns, physician perspectives, treatment accessibility and assumptions influencing the forecast patient population.
Published evidence indicates that cannabis use disorder develops in approximately 10% of regular users and may affect up to 50% of chronic daily users. The Centers for Disease Control and Prevention reported that 52.5 million people, representing approximately 19% of Americans, used cannabis at least once in 2021. Changing legalization policies, broader social acceptance and increasing medical use may influence future consumption patterns and the diagnosed CUD population, including among older adults.
Clinical diagnosis may incorporate toxicology testing of urine, blood, saliva or hair alongside patient history, behavioral assessment and evaluation for psychiatric or medical comorbidities. Additional laboratory testing or imaging may be required when clinicians need to exclude alternative causes of cognitive, behavioral or neurological symptoms.
Current Treatment Landscape and Unmet Medical Need
There are currently no approved pharmacological therapies specifically indicated for cannabis use disorder. Management primarily relies on behavioral and symptomatic interventions, including cognitive behavioral therapy, motivational enhancement therapy and contingency management. These approaches can reduce cannabis consumption and related harms, although sustained abstinence remains difficult for many patients.
Investigational and off-label pharmacological approaches have included tetrahydrocannabinol formulations, gabapentin, N-acetylcysteine and cannabidiol. Evidence remains inconclusive, reinforcing the need for rigorously evaluated therapies that can address withdrawal symptoms, relapse risk, craving and long-term functional outcomes.
Emerging Cannabis Use Disorder Drugs
PP-01 - PleoPharma: PP-01 is an orally administered clinical candidate being evaluated for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder. In February 2025, the US Food and Drug Administration granted Fast Track designation to PP-01 for cannabis withdrawal syndrome, underscoring the need for new treatment options.
AEF0117 - Aelis Farma: AEF0117 is a synthetic signaling-specific inhibitor targeting the cannabinoid type 1 receptor. Earlier clinical studies reported reductions in the positive subjective and reinforcing effects of smoked cannabis, alongside favorable safety and tolerability findings. Aelis Farma and Indivior entered into a strategic partnership in June 2021 to advance the candidate's development.
Cannabis Use Disorder Market Outlook
The cannabis use disorder therapeutics market is expected to evolve through 2034, supported by rising disease recognition, expanding diagnostic activity, technological advances and the potential introduction of novel therapies. The United States accounted for a significant share of the seven-major-market opportunity in 2024, reflecting its comparatively large patient population and treatment-related costs.
The report assesses market size by country, therapy and drug class while evaluating expected uptake, order of entry, clinical efficacy, safety, regulatory status, reimbursement conditions and probability of commercial success. Market access analysis includes country-specific healthcare systems, health technology assessments, reimbursement policies and barriers affecting treatment availability.
Competitive Intelligence and Strategic Value
Insights from more than 15 interviewed key opinion leaders across the seven major markets support the report's analysis of treatment practices, unmet needs and emerging clinical opportunities. Participating experts were affiliated with leading institutions, including the Medical University of South Carolina, UCLA Center for Cannabis and Cannabinoids, University of Barcelona, Columbia University and University of Leeds.
The report also examines collaborations, licensing agreements, mergers and acquisitions, patents and pipeline development activity. Competitive intelligence tools, including SWOT analysis and market-entry assessment, help stakeholders evaluate the positioning of current and emerging cannabis use disorder therapies.
Key Report Benefits
The report enables pharmaceutical companies, investors, healthcare organizations and other industry stakeholders to assess the changing cannabis use disorder market, identify commercial opportunities and develop evidence-based strategies for emerging treatments through 2034.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
3.1. Market Share (%) Distribution by Therapies in 2024
3.2. Market Share (%) Distribution by Therapies in 2034
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Types
7.3. Causes
7.4. Pathophysiology
7.5. Symptoms
7.6. Risk Factor
7.7. Diagnosis
7.7.1. Diagnostic Algorithm
7.7.2. Diagnostic Guidelines
7.8. Treatment and Management
7.8.1. Treatment Algorithm
7.8.2. Treatment Guidelines
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.3. Total Prevalent Cases of Cannabis Use Disorder in the 7MM
8.4. Total Diagnosed Prevalent Cases of Cannabis Use Disorder in the 7MM
8.5. The US
8.5.1. Total Prevalent Cases of Cannabis Use Disorder
8.5.2. Total Diagnosed Prevalent Cases of Cannabis Use Disorder
8.5.3. Age-specific Cases of Cannabis Use Disorder
8.5.4. Gender-specific Cases of Cannabis Use Disorder
8.5.5. Treated Cases of Cannabis Use Disorder
8.6. EU4 and the UK
8.6.1. Total Prevalent Cases of Cannabis Use Disorder
8.6.2. Total Diagnosed Prevalent Cases of Cannabis Use Disorder
8.6.3. Age-specific Cases of Cannabis Use Disorder
8.6.4. Gender-specific Cases of Cannabis Use Disorder
8.6.5. Treated Cases of Cannabis Use Disorder
8.7. Japan
8.7.1. Total Prevalent Cases of Cannabis Use Disorder
8.7.2. Total Diagnosed Prevalent Cases of Cannabis Use Disorder
8.7.3. Age-specific Cases of Cannabis Use Disorder
8.7.4. Gender-specific Cases of Cannabis Use Disorder
8.7.5. Treated Cases of Cannabis Use Disorder
9. Patient Journey
10. Emerging Therapies
10.1. Key Cross Competition
10.2. PP-01: PleoPharma
10.2.1. Drug Description
10.2.2. Other Development Activities
10.2.3. Clinical Trials Information
10.2.4. Safety and Efficacy
10.2.5. Analysts' Views
10.3. AEF0117: Aelis Farma
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Trials Information
10.3.4. Safety and Efficacy
10.3.5. Analysts' Views
To be continued in the report..
11. Cannabis Use Disorder: Seven Major Market Analysis
11.1. Key Findings
11.2. Key Market Forecast Assumptions
11.2.1. Cost Assumptions and Rebates
11.2.2. Pricing Trends
11.2.3. Analogue Assessment
11.2.4. Launch Year and Therapy Uptake
11.3. Market Outlook
11.4. Attribute Analysis
11.5. Total Market Size of Cannabis Use Disorder in the 7MM
11.6. Market Size of Cannabis Use Disorder by Therapies in the 7MM
11.7. The US Market Size
11.7.1. Total Market Size of Cannabis Use Disorder
11.7.2. Market Size of Cannabis Use Disorder by Therapies
11.8. EU4 and the UK Market Size
11.8.1. Total Market Size of Cannabis Use Disorder
11.8.2. Market Size of Cannabis Use Disorder by Therapies
11.9. Japan Market Size
11.9.1. Total Market Size of Cannabis Use Disorder
11.9.2. Market Size of Cannabis Use Disorder by Therapies
12. Key Opinion Leaders' Views
13. Unmet Needs
14. SWOT Analysis
15. Cannabis Use Disorder Market Access and Reimbursement
15.1. United States
15.1.1. Centre for Medicare and Medicaid Services (CMS)
15.2. EU4 and the UK
15.2.1. Germany
15.2.2. France
15.2.3. Italy
15.2.4. Spain
15.2.5. United Kingdom
15.3. Japan
15.3.1. MHLW
16. Appendix
16.1. Bibliography
16.2. Abbreviations and Acronyms
16.3. Report Methodology
17. Publisher Capabilities
18. Disclaimer
19. About the Publisher
List of Tables
Table 1: Total Prevalent Cases of Cannabis Use Disorder in the 7MM (2020-2034)
Table 2: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in the 7MM (2020-2034)
Table 3: Total Prevalent Cases of Cannabis Use Disorder in the US (2020-2034)
Table 4: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in the US (2020-2034)
Table 5: Age-specific Cases of Cannabis Use Disorder in the US (2020-2034)
Table 6: Gender-specific Cases of Cannabis Use Disorder in the US (2020-2034)
Table 7: Treated Cases of Cannabis Use Disorder in the US (2020-2034)
Table 8: Total Prevalent Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Table 9: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Table 10: Age-specific Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Table 11: Gender-specific Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Table 12: Treated Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Table 13: Total Prevalent Cases of Cannabis Use Disorder in Japan (2020-2034)
Table 14: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in Japan (2020-2034)
Table 15: Age-specific Cases of Cannabis Use Disorder in Japan (2020-2034)
Table 16: Gender-specific Cases of Cannabis Use Disorder in Japan (2020-2034)
Table 17: Treated Cases of Cannabis Use Disorder in Japan (2020-2034)
Table 18: Comparison of Emerging Drugs
Table 19: PP-01, Clinical Trial Description, 2025
Table 20: AEF0117, Clinical Trial Description, 2025
Table 21: Key Market Forecast Assumption of Cannabis Use Disorder in the US
Table 22: Key Market Forecast Assumption of Cannabis Use Disorder in EU4 and the UK
Table 23: Key Market Forecast Assumption of Cannabis Use Disorder in Japan
Table 24: Total Market Size of Cannabis Use Disorder in the 7MM (2020-2034)
Table 25: Cannabis Use Disorder Market Size by Therapies in the 7MM (2020-2034)
Table 26: Total Market Size of Cannabis Use Disorder in the US (2020-2034)
Table 27: Cannabis Use Disorder Market Size by Therapies in the US (2020-2034)
Table 28: Total Market Size of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Table 29: Cannabis Use Disorder Market Size by Therapies in EU4 and the UK (2020-2034)
Table 30: Total Market Size of Cannabis Use Disorder in Japan (2020-2034)
Table 31: Cannabis Use Disorder Market Size by Therapies in Japan (2020-2034)
List of Figures
Figure 1: Total Prevalent Cases of Cannabis Use Disorder in the 7MM (2020-2034)
Figure 2: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in the 7MM (2020-2034)
Figure 3: Total Prevalent Cases of Cannabis Use Disorder in the US (2020-2034)
Figure 4: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in the US (2020-2034)
Figure 5: Age-specific Cases of Cannabis Use Disorder in the US (2020-2034)
Figure 6: Gender-specific Cases of Cannabis Use Disorder in the US (2020-2034)
Figure 7: Treated Cases of Cannabis Use Disorder in the US (2020-2034)
Figure 8: Total Prevalent Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Figure 9: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Figure 10: Age-specific Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Figure 11: Gender-specific Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Figure 12: Treated Cases of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Figure 13: Total Prevalent Cases of Cannabis Use Disorder in Japan (2020-2034)
Figure 14: Total Diagnosed Prevalent Cases of Cannabis Use Disorder in Japan (2020-2034)
Figure 15: Age-specific Cases of Cannabis Use Disorder in Japan (2020-2034)
Figure 16: Gender-specific Cases of Cannabis Use Disorder in Japan (2020-2034)
Figure 17: Treated Cases of Cannabis Use Disorder in Japan (2020-2034)
Figure 18: Patient Journey
Figure 19: Total Market Size of Cannabis Use Disorder in the 7MM (2020-2034)
Figure 20: Cannabis Use Disorder Market Size by Therapies in the 7MM (2020-2034)
Figure 21: Total Market Size of Cannabis Use Disorder in the US (2020-2034)
Figure 22: Cannabis Use Disorder Market Size by Therapies in the US (2020-2034)
Figure 23: Total Market Size of Cannabis Use Disorder in EU4 and the UK (2020-2034)
Figure 24: Cannabis Use Disorder Market Size by Therapies in EU4 and the UK (2020-2034)
Figure 25: Total Market Size of Cannabis Use Disorder in Japan (2020-2034)
Figure 26: Cannabis Use Disorder Market Size by Therapies in Japan (2020-2034)
Figure 27: Unmet Needs
Figure 28: SWOT Analysis
Figure 29: Health Technology Assessment
Figure 30: Reimbursement Process in Germany
Figure 31: Reimbursement Process in France
Figure 32: Reimbursement Process in Italy
Figure 33: Reimbursement Process in Spain
Figure 34: Reimbursement Process in the United Kingdom
Figure 35: Reimbursement Process in Japan
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/ywgy6a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.